Bristol Myers Squibb returned to reinvest in the cardiac disease therapy developer having backed its 2017 series A round with Boehringer Ingelheim.

Cardior Pharmaceuticals, a Germany-based developer of therapeutics for cardiac diseases based on research at Hannover Medical School, closed a €64m ($76m) series B round today featuring pharmaceutical firm Bristol Myers Squibb (BMS).

The round was led by venture capital firm Inkef Capital and included Fund+, Sunstone Life Science Ventures, Hadean Ventures, Coparion, LSP, BioMedPartners and High-Tech Gründerfonds (HTGF).

Founded in 2016, Cardior is working on non-coding RNA-based therapeutics that would be capable of preventing, repairing and reversing heart diseases by…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn